OBJECTIVES:  To compare treatment persistence of depot antipsychotic haloperidol decanoate and 2 long-acting injectable antipsychotics: risperidone microspheres, olanzapine pamoate in schizophrenia patients with min. 4 weeks of documented persistent lack of compliance in Polish outpatient reimbursement setting, based on the panel data from open pharmacies. Age and gender distribution, treatment restart rates and maintenance dose distribution were also investigated. METHODS:  Transaction data from the IMS LRx Database which covers 4.227 out of a universe of 14.400 pharmacies in Poland were evaluated. Study population was limited to patients who filled at least one prescription for one of the investigated products in the period 01.11.2013 – 31.10.2014 (inclusion period). All included patients were observed for 365 days from day 1 (observation period). Delay in refilling prescription for the investigated products could not exceed 28 days. Treatment persistence was assessed until discontinuation or end of the study period using Kaplan-Meier survival analysis and Cox proportional hazard model. RESULTS:  Three patient cohorts were identified: receiving risperidone LAI (n=812) or olanzapine LAI (n=116) or haloperidol decanoate (n=775). Median time to discontinuation for haloperidol decanoate was 27 days (95% CI: 26.64-27.36 days), while for both risperidone LAI and olanzapine LAI was considerably longer: risperidone LAI 124 days (95% CI: 111.4-136.6 days) and olanzapine LAI 124 days (95% CI: 61.63-186.37 days). Significantly higher risk for treatment discontinuation was observed for haloperidol decanoate compared to risperidone LAI and olanzapine LAI (HR: 3.16, 95% CI: 2.83-3.52 and 3.31, 95% CI: 2.7-4.05 respectively; p<0.001 for both). Difference in risk of treatment discontinuation between risperidone LAI and olanzapine LAI was statistically insignificant (HR: 0.95, 95% CI: 0.78-1.14, p=0.53). CONCLUSIONS:  Significantly longer treatment persistence and reduced risk of discontinuation were observed for risperidone LAI and olanzapine LAI compared to haloperidol decanoate despite reimbursement restrictions for atypical injectable antipsychotics in Polish outpatient setting.